Dr. Meaglia earns Center of Excellence designation for UroLift

NeoTract Designates Dr. James Meaglia as UroLift^® Center of Excellence

Designation Recognizes Dr. Meaglia’s Commitment to Exemplary Care, Extensive UroLift^® System Experience

PLEASANTON, Calif. (July 21, 2020 via PRWeb) – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that James Meaglia, M.D., Orange County Urology Associates in Mission Viejo, CA, has been designated as a UroLift^® Center of Excellence.

James Meaglia, M.D

The designation recognizes that Dr. Meaglia has achieved a high level of training and experience with the UroLift^® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Dr. Meaglia has performed more than 200 UroLift implant procedures.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

“Dr. James Meaglia has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift^® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.

About Orange County Urology Associates (OCUA)

Orange County Urology Associates is a state-of-the-art, large urology practice serving all of Orange County with offices in Laguna Hills, Irvine, Mission Viejo (two convenient locations), San Clemente, Fountain Valley and Newport Beach. OCUA also treats patients from Los Angeles, San Diego, Anaheim, Irvine, Laguna Beach, Lake Forest, Huntington Beach and Long Beach. We also treat patients from around the world. OCUA provides complete male, female and pediatric urology care. Our 11 experienced urologists consistently deliver expert care, utilizing the latest technology and techniques, with advanced diagnostic tests and minimally invasive surgeries.

The urologists at OCUA, along with the 70 physician assistants, nurses and office staff, provide exceptional personalized care. They pay careful attention to the special needs of each individual patient and all family members. They offer diagnosis and solutions for the full spectrum of urologic conditions, including:

• Bladder control problems
• Overactive bladder
• Neurogenic bladder
• Pain when urinating
• Blood in urine
• Urinary tract infection
• Prostatitis
• Prostate enlargement
• Prostate cancer
• Premature ejaculation
• Impotence
• Kidney stones
• Kidney cancer
• Urology surgical procedures
• da Vinci^® robotic nephrectomy
• da Vinci^® robotic prostatectomy
• Male reconstructive surgery
• Overactive bladder treatments
• Male infertility treatment
• Urinary incontinence treatment (including female urinary incontinence treatment)
• Prostatitis treatment
• Prostate cancer treatment
• ED treatments
• Curved penis treatment
• Vasectomy & vasectomy reversal
• ESWL
• STD treatments
• Testicular cancer treatment

Orange County Urology Associates is a member of LUGPA, the Large Urology Group Practice Association, which represents more than 1,800 urologists across the country. LUGPA’s goal is to provide urological surgeons in large group practices the means to access resources, technology and management tools so they can provide their services in an efficient, cost effective and clinically superior manner.

Discover today’s most advanced, effective urology care. Trust Orange County Urology Associates for real solutions. Call us at 949.855.1101 or visit us on the Web at: www.orangecountyurology.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.

Teleflex is the home of Arrow^®, Deknatel^®, Hudson RCI^®, LMA^®, Pilling^®, Rusch^®, UroLift^® and Weck^® – trusted brands united by a common sense of purpose.

For Teleflex Incorporated: Jake Elguicze, 610.948.2836 Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

• Roehrborn, J Urology 2013 LIFT Study
• McVary, J Sex Med 2016